동물 의약품 시장 규모, 점유율 및 동향 분석 보고서 : 대상 동물별, 제품 유형별, 약제 유형별, 제형별, 투여 경로별, 판매 채널별, 지역별 및 부문별 전망(2026-2033년)

Veterinary Pharmaceuticals Market Summary

The global veterinary pharmaceuticals market size was valued at USD 30.3 billion in 2025 and is projected to grow from USD 33.3 billion in 2026 to USD 68.6 billion by 2033, at a CAGR of 10.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 36.1% in 2025. Market growth is driven by factors such as increasing demand for preventive and therapeutic pharmaceuticals, rising pet ownership and animal healthcare spending, expansion of livestock production, and technological advancements in veterinary drug formulation and delivery systems.

Market Concentration & Characteristics

The veterinary pharmaceuticals market is in a high-growth stage, with the pace of growth accelerating. The market is characterized by increasing demand for preventive and therapeutic medicines, rising companion animal healthcare spending, expansion of livestock production, technological advancements in drug formulation and delivery systems, portfolio diversification, stringent regulatory requirements, strategic collaborations, M&A activity, and regional expansion of veterinary healthcare services.

These integrated pillars directly catalyze market expansion by broadening total addressable markets, unlocking premium pricing tiers, and shortening time-to-revenue. By resolving critical industry pain points such as owner compliance friction, farm labor shortages, and strict residue regulations, pharmaceutical leaders can protect gross margins against generic erosion. Crucially, transitioning from transactional drug sales to data-enabled, precision-health platforms shifts the sector toward higher-margin, recurring revenue models, driving sustained long-term valuation growth.

The market is witnessing continuous innovation through advances in long-acting formulations, sustained-release drug delivery, species-specific formulations, combination therapies, and improved dosage forms. Development of injectable, oral, topical, and transdermal formulations is improving treatment convenience, dosing efficiency, and administration across companion and production animals. Furthermore, advancements in formulation technologies, pharmaceutical manufacturing, and analytical testing are supporting the development of specialized veterinary medicines and differentiated drug delivery formats.

Regulatory requirements established by agencies such as the FDA, EMA, and other national veterinary pharmaceutical authorities have a high impact on product development, manufacturing, approval, distribution, and commercialization. Requirements related to safety, efficacy, residue limits, manufacturing quality, product stability, labeling, and pharmacovigilance influence development timelines and market entry. Furthermore, tighter requirements governing antimicrobial use, veterinary drug residues, and product manufacturing are increasing compliance costs and raising the regulatory capabilities required for successful commercialization.

Mergers and acquisitions are contributing to market development by enabling animal health companies to expand pharmaceutical portfolios, therapeutic capabilities, geographic presence, manufacturing capacity, and distribution networks. Strategic acquisitions across animal health and pharmaceutical sectors provide access to established products, development pipelines, manufacturing facilities, specialized technologies, and regional markets. Furthermore, consolidation among animal health distributors and pharmaceutical companies is strengthening integrated commercial capabilities. M&A activity is expected to remain relevant as companies seek to broaden their presence across companion animal and livestock pharmaceutical markets.

Increasing demand for preventive and therapeutic animal healthcare is encouraging manufacturers to expand product portfolios across multiple pharmaceutical categories. Products include antibiotics, antiparasitic, vaccines, analgesics, anti-inflammatory drugs, dermatology medicines, cardiovascular drugs, and other therapeutic products. Moreover, manufacturers are expanding into long-acting formulations, combination therapies, species-specific medicines, and alternative delivery formats to address diverse treatment requirements. Portfolio expansion is also supporting greater coverage of chronic conditions, specialty indications, and underserved animal populations, enabling companies to strengthen their presence across veterinary practices, livestock operations, and companion animal healthcare.

The market is experiencing regional expansion across North America, Europe, Asia Pacific, Latin America, and other emerging markets. North America maintains a strong position due to established veterinary healthcare infrastructure, high companion animal healthcare expenditure, advanced pharmaceutical capabilities, and the presence of established animal health companies. Europe also has a developed veterinary pharmaceutical ecosystem supported by established regulatory systems, pharmaceutical capabilities, and animal healthcare services. Furthermore, Asia Pacific is expanding its veterinary pharmaceutical capabilities due to increasing livestock production, rising companion animal ownership, improving veterinary infrastructure, growing animal healthcare expenditure, and increasing availability of veterinary pharmaceutical products.

Global Veterinary Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary pharmaceuticals market report based on animal, product, drug type, type, route of administration, end use, and region:

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Production Animals
  • Poultry
  • Swine
  • Bovine
  • Ovine & Caprine
  • Others
• Companion Animals
  • Canine
  • Feline
  • Equine
  • Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Parasiticides
• Anti-infectives
• Anti-inflammatory
• Analgesics
• Other Products
• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded
• Generics
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription
• OTC
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Other Routes
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Institutional Sales
• Veterinary Pharmacies & Retail
• E-commerce
• Other Channels
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Animal
  • 1.2.2. Product
  • 1.2.3. Drug Type
  • 1.2.4. Type
  • 1.2.5. Route of Administration
  • 1.2.6. Sales Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Pharmaceuticals Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Product Pipeline Analysis
• 3.7. User Perspective Analysis
• 3.8. Value Chain Analysis
  • 3.8.1. Supply Trends
  • 3.8.2. Demand Trends
• 3.9. Market Analysis Tools
  • 3.9.1. Porter's Five Force Analysis
  • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Pharmaceuticals Market: Animal Estimates & Trend Analysis

• 4.1. Veterinary Pharmaceuticals Market, By Animal: Segment Dashboard
• 4.2. Veterinary Pharmaceuticals Market, By Animal: Movement Analysis
• 4.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Animal, 2021 - 2033 (USD Million)
• 4.4. Production Animals
  • 4.4.1. Production Animals Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.4.2. Poultry
    • 4.4.2.1. Poultry Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.4.3. Swine
    • 4.4.3.1. Swine Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.4.4. Bovine
    • 4.4.4.1. Bovine Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.4.5. Ovine & Caprine
    • 4.4.5.1. Ovine & Caprine Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.5. Companion Animals
  • 4.5.1. Companion Animals Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.2. Canine
    • 4.5.2.1. Canine Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.3. Feline
    • 4.5.3.1. Feline Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.4. Equine
    • 4.5.4.1. Equine Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 5. Veterinary Pharmaceuticals Market: Product Estimates & Trend Analysis

• 5.1. Veterinary Pharmaceuticals Market, By Product: Segment Dashboard
• 5.2. Veterinary Pharmaceuticals Market, By Product: Movement Analysis
• 5.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. Parasiticides
  • 5.4.1. Parasiticides Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 5.5. Anti-infectives
  • 5.5.1. Anti-infectives Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 5.6. Anti-inflammatory
  • 5.6.1. Anti-inflammatory Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 5.7. Analgesics
  • 5.7.1. Analgesics Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 5.8. Other Products
  • 5.8.1. Other Products Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 6. Veterinary Pharmaceuticals Market: Drug Type Estimates & Trend Analysis

• 6.1. Veterinary Pharmaceuticals Market, By Drug type: Segment Dashboard
• 6.2. Veterinary Pharmaceuticals Market, By Drug type: Movement Analysis
• 6.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Drug type, 2021 - 2033 (USD Million)
• 6.4. Branded
  • 6.4.1. Branded Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 6.5. Generics
  • 6.5.1. Generics Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Pharmaceuticals Market: Type Estimates & Trend Analysis

• 7.1. Veterinary Pharmaceuticals Market, By Type: Segment Dashboard
• 7.2. Veterinary Pharmaceuticals Market, By Type: Movement Analysis
• 7.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 7.4. Prescription
  • 7.4.1. Prescription Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.5. OTC
  • 7.5.1. OTC Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Pharmaceuticals Market: Route of Administration Estimates & Trend Analysis

• 8.1. Veterinary Pharmaceuticals Market, By Route of Administration: Segment Dashboard
• 8.2. Veterinary Pharmaceuticals Market, By Route of Administration: Movement Analysis
• 8.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Route of Administration, 2021 - 2033 (USD Million)
• 8.4. Oral
  • 8.4.1. Oral Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.5. Injectable
  • 8.5.1. Injectable Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.6. Topical
  • 8.6.1. Topical Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.7. Other Routes
  • 8.7.1. Other Routes Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Veterinary Pharmaceuticals Market: Sales Channel Estimates & Trend Analysis

• 9.1. Veterinary Pharmaceuticals Market, By Sales Channel: Segment Dashboard
• 9.2. Veterinary Pharmaceuticals Market, By Sales Channel: Movement Analysis
• 9.3. Veterinary Pharmaceuticals Market Estimates & Forecasts, By Sales Channel, 2021 - 2033 (USD Million)
• 9.4. Institutional Sales
  • 9.4.1. Institutional Sales Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.5. Veterinary Pharmacies & Retail
  • 9.5.1. Veterinary Pharmacies & Retail Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.6. E-commerce
  • 9.6.1. E-commerce Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.7. Other Channels
  • 9.7.1. Other Channels Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Veterinary Pharmaceuticals Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market Share Analysis, 2025 & 2033
• 10.3. North America
  • 10.3.1. North America Veterinary Pharmaceuticals Market Estimates & Forecasts, By Country, 2021 - 2033 (USD Million)
  • 10.3.2. U.S.
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Regulatory Framework
    • 10.3.2.4. U.S. Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Regulatory Framework
    • 10.3.3.4. Canada Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Competitive Scenario
    • 10.3.4.3. Regulatory Framework
    • 10.3.4.4. Mexico Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.2. UK
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. UK Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Germany Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. France Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Regulatory Framework
    • 10.4.5.4. Italy Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Regulatory Framework
    • 10.4.6.4. Spain Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Regulatory Framework
    • 10.4.7.4. Denmark Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Regulatory Framework
    • 10.4.8.4. Sweden Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Regulatory Framework
    • 10.4.9.4. Norway Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.2. Japan
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. Japan Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.3. China
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. China Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. India Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.5. Australia
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Australia Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.6. South Korea
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. South Korea Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.5.7. Thailand
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Thailand Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Framework
    • 10.6.2.4. Brazil Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Framework
    • 10.6.3.4. Argentina Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 10.7. Middle East and Africa
  • 10.7.1. Middle East and Africa Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.2. South Africa
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Framework
    • 10.7.2.4. South Africa Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.3. Saudi Arabia
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Regulatory Framework
    • 10.7.3.3. Saudi Arabia Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.4. UAE
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Framework
    • 10.7.4.4. UAE Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Framework
    • 10.7.5.4. Kuwait Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.6. Oman
    • 10.7.6.1. Key Country Dynamics
    • 10.7.6.2. Competitive Scenario
    • 10.7.6.3. Regulatory Framework
    • 10.7.6.4. Kuwait Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 10.7.7. Qatar
    • 10.7.7.1. Key Country Dynamics
    • 10.7.7.2. Competitive Scenario
    • 10.7.7.3. Regulatory Framework
    • 10.7.7.4. Kuwait Veterinary Pharmaceuticals Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Key Participant Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Company Market Position Analysis, 2025
• 11.3. Estimated Company Market Share Analysis, 2025
• 11.4. Company Categorization
• 11.5. Company Profiles/Listing
  • 11.5.1. ZOETIS INC.
    • 11.5.1.1. Company Overview
    • 11.5.1.2. Financial performance
    • 11.5.1.3. Product benchmarking
    • 11.5.1.4. Strategic initiatives
  • 11.5.2. Boehringer Ingelheim International Gmbh
    • 11.5.2.1. Company Overview
    • 11.5.2.2. Financial performance
    • 11.5.2.3. Product benchmarking
    • 11.5.2.4. Strategic initiatives
  • 11.5.3. Merck & Co., Inc.
    • 11.5.3.1. Company Overview
    • 11.5.3.2. Financial performance
    • 11.5.3.3. Product benchmarking
    • 11.5.3.4. Strategic initiatives
  • 11.5.4. Elanco
    • 11.5.4.1. Company Overview
    • 11.5.4.2. Financial performance
    • 11.5.4.3. Product benchmarking
    • 11.5.4.4. Strategic initiatives
  • 11.5.5. Dechra
    • 11.5.5.1. Company Overview
    • 11.5.5.2. Financial performance
    • 11.5.5.3. Product benchmarking
    • 11.5.5.4. Strategic initiatives
  • 11.5.6. Ceva Sante Animale
    • 11.5.6.1. Company Overview
    • 11.5.6.2. Financial performance
    • 11.5.6.3. Product benchmarking
    • 11.5.6.4. Strategic initiatives
  • 11.5.7. Phibro Animal Health Corporation
    • 11.5.7.1. Company Overview
    • 11.5.7.2. Financial performance
    • 11.5.7.3. Product benchmarking
    • 11.5.7.4. Strategic initiatives
  • 11.5.8. Virbac
    • 11.5.8.1. Company Overview
    • 11.5.8.2. Financial performance
    • 11.5.8.3. Product benchmarking
    • 11.5.8.4. Strategic initiatives
  • 11.5.9. Bimeda Corporate
    • 11.5.9.1. Company Overview
    • 11.5.9.2. Financial performance
    • 11.5.9.3. Product benchmarking
    • 11.5.9.4. Strategic initiatives
  • 11.5.10. Biogenesis Bago
    • 11.5.10.1. Company Overview
    • 11.5.10.2. Financial performance
    • 11.5.10.3. Product benchmarking
    • 11.5.10.4. Strategic initiatives
  • 11.5.11. Vetoquinol
    • 11.5.11.1. Company Overview
    • 11.5.11.2. Financial performance
    • 11.5.11.3. Product benchmarking
    • 11.5.11.4. Strategic initiatives
  • 11.5.12. Norbrook Laboratories
    • 11.5.12.1. Company Overview
    • 11.5.12.2. Financial performance
    • 11.5.12.3. Product benchmarking
    • 11.5.12.4. Strategic initiatives